BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34692834)

  • 21. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
    Recăreanu F; Simionescu C; Georgescu CV; Pirici E
    Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
    Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
    Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation between Ki67 and histological grade in breast cancer patients treated with preoperative chemotherapy.
    Petric M; Martinez S; Acevedo F; Oddo D; Artigas R; Camus M; Sanchez C
    Asian Pac J Cancer Prev; 2014; 15(23):10277-80. PubMed ID: 25556461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index.
    Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K
    Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Routine assessment of hormonal receptor and her-2/neu status underscores the need for more therapeutic targets in Kenyan women with breast cancer.
    Nyagol J; Nyong'o A; Byakika B; Muchiri L; Cocco M; de Santi MM; Spina D; Bellan C; Lazzi S; Kostopoulos I; Luzi P; Leoncini L
    Anal Quant Cytol Histol; 2006 Apr; 28(2):97-103. PubMed ID: 16637512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic variables in invasive breast cancer: contribution of comedo versus noncomedo in situ component.
    Brower ST; Ahmed S; Tartter PI; Bleiweiss I; Amberson JB
    Ann Surg Oncol; 1995 Sep; 2(5):440-4. PubMed ID: 7496840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-expression of steroid hormone receptors (estrogen receptor alpha and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: clinical outcome following tamoxifen-based adjuvant therapy.
    Gago FE; Fanelli MA; Ciocca DR
    J Steroid Biochem Mol Biol; 2006 Jan; 98(1):36-40. PubMed ID: 16188438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of astrocyte elevated gene-1, basic-fibroblast growth factor, beta-catenin, Ki-67, tumor necrosis factor-alfa with prognostic parameters in ductal carcinomas and ductal intraepithelial neoplasms.
    Erdem H; Gundogdu B; Ankarali H; Yasar M; Sener E; Oktay M; Bahadir A; Uzunlar AK; Gursan N; Ozaydin I; Sahiner C
    Niger J Clin Pract; 2015; 18(5):638-43. PubMed ID: 26096243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in MNU and DMBA-induced mammary tumors in female rats.
    Alvarado A; Lopes AC; Faustino-Rocha AI; Cabrita AMS; Ferreira R; Oliveira PA; Colaço B
    Pathol Res Pract; 2017 May; 213(5):441-446. PubMed ID: 28285967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.
    Jacquemier J; Charafe-Jauffret E; Monville F; Esterni B; Extra JM; Houvenaeghel G; Xerri L; Bertucci F; Birnbaum D
    Breast Cancer Res; 2009; 11(2):R23. PubMed ID: 19405945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Histopathological Markers with Clinico- Pathological Factors in Mexican Women with Breast Cancer.
    Bandala C; De la Garza-Montano P; Cortes-Algara A; Cruz-Lopez J; Dominguez-Rubio R; Gonzalez-Lopez JN; Cardenas-Rodriguez N; Alfaro-Rodriguez A; Salcedo M; Floriano-Sanchez E; Lara-Padilla E
    Asian Pac J Cancer Prev; 2015; 16(18):8397-403. PubMed ID: 26745092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ER-/PR+/HER2- breast cancer type shows the highest proliferative activity among all other combined phenotypes and is more common in young patients: Experience with 6643 breast cancer cases.
    Arena V; Pennacchia I; Vecchio FM; Carbone A
    Breast J; 2019 May; 25(3):381-385. PubMed ID: 30916428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of substance P, neurokinin 1 receptor, Ki-67 and pyruvate kinase M2 in hormone receptor negative breast cancer and evaluation of impact on overall survival.
    Al-Keilani MS; Bdeir R; Elstaty RI; Alqudah MA
    BMC Cancer; 2023 Feb; 23(1):158. PubMed ID: 36797689
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
    Almasri NM; Al Hamad M
    Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study.
    Li FY; Wu SG; Zhou J; Sun JY; Lin Q; Lin HX; Guan XX; He ZY
    PLoS One; 2014; 9(2):e87264. PubMed ID: 24498305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reappraisal of immunohistochemical profiling of special histological types of breast carcinomas: a study of 121 cases of eight different subtypes.
    Alvarenga CA; Paravidino PI; Alvarenga M; Gomes M; Dufloth R; Zeferino LC; Vassallo J; Schmitt FC
    J Clin Pathol; 2012 Dec; 65(12):1066-71. PubMed ID: 22944625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
    Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
    Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.
    Soosanabadi M; Ghahfarokhi AM; Pourghazi F; Ehtesham N; Mirfakhraie R; Atanesyan L; Keyhani E; Behjati F
    Mol Biol Rep; 2022 Sep; 49(9):8547-8553. PubMed ID: 35763181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.